Merck's COVID-19 pill significantly less effective in new analysis
Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported. The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. In October, its data showed a roughly 50% efficacy, based on data from 775 patients. The drug, molnupiravir, was developed with partner Ridgeback Biotherapeutics.
Reuters - November 26, 2021View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/merck-says-covid-19-pill-cuts-hospitalization-death-risk-by-30-2021-11-26/